HUE031555T2 - C-FMS kináz inhibitorai - Google Patents

C-FMS kináz inhibitorai Download PDF

Info

Publication number
HUE031555T2
HUE031555T2 HUE08839490A HUE08839490A HUE031555T2 HU E031555 T2 HUE031555 T2 HU E031555T2 HU E08839490 A HUE08839490 A HU E08839490A HU E08839490 A HUE08839490 A HU E08839490A HU E031555 T2 HUE031555 T2 HU E031555T2
Authority
HU
Hungary
Prior art keywords
dimethyl
exo
enyl
prepared
cyclohex
Prior art date
Application number
HUE08839490A
Other languages
English (en)
Inventor
Carl R Illig
Jinsheng Chen
Sanath K Meegalla
Mark J Wall
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of HUE031555T2 publication Critical patent/HUE031555T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Psychiatry (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)

Claims (3)

  1. SKäbsils!5?ät IgOîYfxaVvH L rksplëfü vggyffkd
    < gkvgOîbyg W jeômàsg
    MplOû c;;a-x>íi. é:; xaekhc-s à làgiviakl«;« iSPxkgyik jHesCvs egyöOstPl FUygcíkOF H. Fi, Cl, 8g I, OH, OOC 00%ΟΙί; SC;;„;:Hy!: >OC;l..,;ajOk SOjC^^gálklk <óHV$Mk CO,RÖ COMROC C-CIO vagy CM, xOx FF' JylsnÇse H vagy -ÇC s., ^síkik ,RS Jetemlve fí vagy -<Csä,,^,si:kfl; R; jdoOévc H vagg··(.',·<. j-alkd; 0: IC jekmOe U, UCCUIvagy 0Χ1-Λ H?ÖH; RF jöisigése OkHaildk sgkö^saufesaFukfi dkivdksMu gafemk .diíidhísxuifenöpf-mfif.k feml„ .fötsmi Mïs-fvfíivögiíidíi vagy íihyragií'aaiS,, amelyek Mrmeiyíke egymäväCi tlJgpfHnil! belyefeftvv letaR: klík. Iffg-ííg hldrö s I k Cj < .-5 sSlkif é% Ci. j .,5,a lk s ! kifei f. megválás ssmf agy vagy ksFö FelysCvs Mveif X jeteméve M, F. Cl vagy Ciig: ijgtegíáse CH vagy N, X jdcnC:vV
    vagy këpteiâ «sögan, és ssökfegn Rvv jöiööisse 14 -C'^^äiyf.» -'CORI-ly, -<R:ë|kHCj,^:,ii||iÎ!, Ci ;N(C;:..^:síiki!ö vagy ·*.'Οί.Ί. ....sikH - vagy egy syötváíjö, hisiril(sa, isigöiMgó vagy miftööögfí §yô§y|SK3i;0kg:a:RkgstÉ® sois. 2. A,:· 1, ígíSí3:V|y«í:íS: iiK£SrS£Si;| Î-egÿüliî£ôS.h<s: W ickiöésv
    képfeil íísypöíí;
    vspy R' tdesSsRi- líápleíii esöpíRí: Ä jPfep#Ss?i!; X RIcíH^H'í
    vagy kS|)íiM ί«ϊΐ5|Κίΐ1? és sgy sægâvééPflïklrétj», to ïs|m|«:figk gjfóg^lsK^élág gkApsfkÁÁ sié|a. A Λ :?. igénypsu szerlni: vegyük-g ahol W jvfeîéësg
    v«§y képiek csőnél: R -· R· R-iïtëss
    vagy képkié eSopgié; έ$ egy svölyiyi, tiiikétk, kkfgékgíy vágy skA
  2. 4. A S íiíCí-ypiíís· vsvnoil vegyi; ki, «huí W jkemésá
    vagy képiek «sàçsîït, és agy s:e3ké|l% lak'ai;i?k !««ie:!;s*je vagy an-vkavk eykgyassapkg séogadivsé sygv ík A 4. igény goni veering vegyesei. she!
    Wj ekeké®
    íkpkk ssagöfk R-; jcieeiése vagy Mgkk ásg|Kkg és égy ssSíiVágás lskéÁgs:; íiisjáviserkvagy SiiiKdvKSk.gyág>4SM!y&amp;g elkgisöhsk ségiv &amp; A,··. 1 sgéevpin-i s/e: esti vngyukiek kitek ;;;·? la képlsk vegyiikíek
    • a kepk-i!:···:«
    vagy: kagSeO csöbört; ijslesîèsaOS! vsg;y N; as X jdví-^ía
    gsyy képksn csípőn, A> ηζηΜχ-ο g kkglkss 11 -(.^...-,ΙκΗ. 11/1..·Α*ί -10111.. 1kl -íkONíl^ vagy A OC//11! - <k <;gy s«kv!xyg. hIsOja, iMOOOf k vagy nsβχ/λΑ pôgyâksmOg ¢1 fôpàhsa#keys,
  3. 1, A k igOiypnl :<ïv(nBs Vvgynkf, skokk'jOsBOs«
    ksplfeil çsiipüiti 8s. syy saOvâtjo di'dkàlja, isiSôrnsÂ" vagy jwksfeæfe gyàgyisgsîilag eifogadhsíö sóiig Ε, A.:·? ; « sges-vp»*;· svinns-ig
    tóptóiö vogvükn és ggy sK?í!vát|^, h kaképp psuioüxsjc vsgy guÄMk gyógyá:>.<\itótóg ítóíugtóba·« ·>;ρ«. tó íhógya?>/ag kes?í:i«érsv, gîgëly: ggygàfegg logis! sgg k igéPypxnî Sâsri&amp;Êf végytólétót és egy gyógy*· sgäOtsg tófógagitóé hocxtósóargagip.. H!, ;,vgui:kk> vgy i. igégyppgi sgeriolf vggÿSfet ostógggtógtóg tó*gv;4:tó\ ípürass mályk gygggiSss ès ss-sPsi gyxiHsdés nsés íom-tó. osont-kukk gy-tóitórtó i-Ptógytótós. «söggöldMgsóS <S gsöptMk nosKs-élPk &amp;!koéa ssoportóo; é®gvg!tógísM g^Pgsog logstósatós vétó tótótósS^m
HUE08839490A 2007-10-17 2008-10-16 C-FMS kináz inhibitorai HUE031555T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US98062307P 2007-10-17 2007-10-17

Publications (1)

Publication Number Publication Date
HUE031555T2 true HUE031555T2 (hu) 2017-07-28

Family

ID=40352814

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE08839490A HUE031555T2 (hu) 2007-10-17 2008-10-16 C-FMS kináz inhibitorai
HUE16203884A HUE056173T2 (hu) 2007-10-17 2008-10-16 C-FMS kináz inhibitorai

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE16203884A HUE056173T2 (hu) 2007-10-17 2008-10-16 C-FMS kináz inhibitorai

Country Status (36)

Country Link
US (1) US8497376B2 (hu)
EP (2) EP3208269B1 (hu)
JP (1) JP5475672B2 (hu)
KR (1) KR101559326B1 (hu)
CN (1) CN101889009B (hu)
AR (1) AR068892A1 (hu)
AU (1) AU2008312540B2 (hu)
BR (1) BRPI0817843B8 (hu)
CA (1) CA2702898C (hu)
CL (1) CL2008003068A1 (hu)
CO (1) CO6270363A2 (hu)
CR (1) CR11433A (hu)
CY (2) CY1118717T1 (hu)
DK (2) DK3208269T3 (hu)
EA (1) EA018936B1 (hu)
ES (2) ES2614754T3 (hu)
HR (2) HRP20211593T1 (hu)
HU (2) HUE031555T2 (hu)
IL (1) IL205043A (hu)
JO (1) JO3240B1 (hu)
LT (2) LT2215079T (hu)
MX (1) MX2010004263A (hu)
MY (1) MY153951A (hu)
NI (1) NI201000059A (hu)
NZ (1) NZ584574A (hu)
PA (1) PA8799701A1 (hu)
PE (1) PE20090972A1 (hu)
PL (2) PL3208269T3 (hu)
PT (2) PT2215079T (hu)
RS (2) RS55860B1 (hu)
SI (2) SI2215079T1 (hu)
TW (1) TWI440637B (hu)
UA (1) UA99311C2 (hu)
UY (1) UY31397A1 (hu)
WO (1) WO2009052237A1 (hu)
ZA (1) ZA201003429B (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060281788A1 (en) * 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
KR101367645B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
CA2649739C (en) 2006-04-20 2015-09-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
TWI510487B (zh) 2010-04-21 2015-12-01 Plexxikon Inc 用於激酶調節的化合物和方法及其適應症
US20120271046A1 (en) 2011-04-19 2012-10-25 Jeffrey Christopher S Nitrogen-containing heterocyclic compounds and methods of making the same
EP2882757B1 (en) 2012-08-07 2016-10-05 Janssen Pharmaceutica, N.V. Process for the preparation of heterocyclic ester derivatives
JOP20180012A1 (ar) * 2012-08-07 2019-01-30 Janssen Pharmaceutica Nv عملية السلفنة باستخدام نونافلوروبوتانيسولفونيل فلوريد
JP6262732B2 (ja) 2012-08-16 2018-01-17 ヤンセン ファーマシューティカ エヌ．ベー． Ｎ型カルシウムチャネル遮断剤としての置換ピラゾール
PL2970232T3 (pl) 2013-03-15 2018-08-31 Janssen Pharmaceutica Nv Podstawione pochodne pirydyny użyteczne jako inhibitory kinazy c-FMS
US20160015700A1 (en) * 2013-03-15 2016-01-21 Carla DE BOER 4-cyano-n-(2-(4,4-dimethylcyclohex-1-en-1-yl)-6-(2,2,6,6-tetramethyltetrahydro-2h-pyran-4-yl)pyridin-3-yl)-1h-imidazole-2-carboxamide for the treatment of hodgkin's lymphoma
CA2921298C (en) * 2013-08-16 2021-07-27 Janssen Pharmaceutica Nv Substituted imidazoles as n-type calcium channel blockers
US9453002B2 (en) 2013-08-16 2016-09-27 Janssen Pharmaceutica Nv Substituted imidazoles as N-type calcium channel blockers
GB201315487D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
US9670174B2 (en) * 2013-12-19 2017-06-06 Archer Daniels Midland Company Mono- and dialkyl ethers of furan-2,5-dimethanol and (tetra-hydrofuran-2,5-diyl)dimethanol and amphiphilic derivatives thereof
JP6537338B2 (ja) * 2015-04-24 2019-07-03 日東電工株式会社 核酸固相合成用リンカー及び担体
KR20180107142A (ko) * 2016-02-11 2018-10-01 바이엘 크롭사이언스 악티엔게젤샤프트 해충 방제제로서의 치환된 2-옥시이미다졸릴-카르복스아미드
TWI752980B (zh) * 2016-07-18 2022-01-21 比利時商健生藥品公司 4-氰基-n-(2-(4,4-二甲基環己-1-烯-1-基)-6-(2,2,6,6-四甲基四氫-2h-哌喃-4-基)吡啶-3-基)-1h-咪唑-2-甲醯胺之晶型
TW201811326A (zh) 2016-07-18 2018-04-01 比利時商健生藥品公司 ４－氰基－ｎ－（２－（４，４－二甲基環己－１－烯－１－基）－６－（２，２，６，６－四甲基四氫－２ｈ－哌喃－４－基）吡啶－３－基）－１ｈ－咪唑－２－甲醯胺之鹽形式
WO2018160917A1 (en) 2017-03-03 2018-09-07 Janssen Biotech, Inc. Co-therapy comprising a small molecule csf-1r inhibitor and an agonistic antibody that specifically binds cd40 for the treatment of cancer
JOP20190282A1 (ar) 2017-06-09 2019-12-05 Novartis Ag مركبات وتركيبات لحث تكوّن الغضاريف
CN109467538A (zh) * 2017-09-07 2019-03-15 和记黄埔医药（上海）有限公司 环烯烃取代的杂芳环类化合物及其用途
BR112021011894A2 (pt) 2018-12-21 2021-09-08 Daiichi Sankyo Company, Limited Composição farmacêutica
WO2020222109A1 (en) 2019-05-02 2020-11-05 Janssen Biotech, Inc. Csf-1/csf-1r gene set
CN110575450B (zh) * 2019-09-17 2023-03-31 遵义医科大学珠海校区 2,5-呋喃二甲醇在制备抗肿瘤药物中的应用
WO2021144360A1 (en) 2020-01-17 2021-07-22 F. Hoffmann-La Roche Ag Small molecule csf-1r inhibitors in therapeutic and cosmetic uses

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2466420A (en) 1947-11-26 1949-04-05 Eastman Kodak Co Ketene condensation products with aldehydes
US3226394A (en) 1964-06-16 1965-12-28 Shulton Inc Pyridylethylated anthranilamides and derivatives thereof
CH504416A (de) 1966-12-05 1971-03-15 Ciba Geigy Ag Verfahren zur Herstellung von aromatischen Sulfamoylverbindungen
US4551540A (en) 1983-01-17 1985-11-05 Borg-Warner Chemicals, Inc. Substituted 2,5-dimethylpyrroles
US5190541A (en) 1990-10-17 1993-03-02 Boston Scientific Corporation Surgical instrument and method
CA2131528C (en) 1992-03-05 2004-07-13 Philip E. Thorpe Methods and compositions for targeting the vasculature of solid tumors
US5474765A (en) 1992-03-23 1995-12-12 Ut Sw Medical Ctr At Dallas Preparation and use of steroid-polyanionic polymer-based conjugates targeted to vascular endothelial cells
US5686472A (en) 1992-10-29 1997-11-11 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5593992A (en) 1993-07-16 1997-01-14 Smithkline Beecham Corporation Compounds
EP0785937A1 (en) 1994-10-14 1997-07-30 Smithkline Beecham Plc 2-(imidazol-4-yl)carbapeneme derivatives, intermediates thereof and use as antibacterials
BR9608021A (pt) 1995-04-19 1999-03-02 Schneider Inc Dispositivo expansível revestido de libertação de droga
US6117432A (en) 1995-04-20 2000-09-12 Societe D'exploitation De Produits Pour Les Industries Chimiques (S.E.P.P.I.C.) Therapeutic composition comprising an antigen or an in vivo generator of a compound comprising an amino acid sequence
TW349948B (en) 1995-10-31 1999-01-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 2-quinolone derivatives
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1997021701A1 (en) 1995-12-08 1997-06-19 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibiting (imidazol-5-yl)methyl-2-quinolinone derivatives
US5874442A (en) 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US5702390A (en) 1996-03-12 1997-12-30 Ethicon Endo-Surgery, Inc. Bioplar cutting and coagulation instrument
JPH11514676A (ja) 1996-08-09 1999-12-14 メルク エンド カンパニー インコーポレーテッド 立体選択的脱酸素化反応
DE69725604T2 (de) 1996-12-20 2005-03-03 Sergazy Mynzhasarovich Adekenov VERFAHREN UND GERÄT ZUR HERSTELLUNG VPM LYOPHILISIERTEM 1ß, 10ß-EPOXY-13-DIMETHYLAMINO-GUAIA-3(4)-EN-6,12-OLID-HYDROCHLORID
UA59384C2 (uk) 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
CA2288140C (en) 1997-04-25 2007-04-03 Janssen Pharmaceutica N.V. Farnesyltransferase inhibiting quinazolinones
TW491872B (en) 1997-05-27 2002-06-21 Ciba Sc Holding Ag Block oligomers containing l-hydrocarbyloxy-2,2,6,6-tetramethyl-4- piperidyl groups as stabilizers for lower polyolefin
US6100254A (en) 1997-10-10 2000-08-08 Board Of Regents, The University Of Texas System Inhibitors of protein tyrosine kinases
JP4022044B2 (ja) 1998-03-05 2007-12-12 フォーミュラ ワン アドミニストレイション リミテッド データ通信システム
US6303654B1 (en) 1998-03-12 2001-10-16 Wisconsin Alumni Research Foundation Acyclic monoterpenoid derivatives
AU5086499A (en) 1998-07-01 2000-01-24 Merck & Co., Inc. Process for making farnesyl-protein transferase inhibitors
AU747427B2 (en) 1998-07-10 2002-05-16 Merck & Co., Inc. Novel angiogenesis inhibitors
ID27562A (id) 1998-08-27 2001-04-12 Pfizer Prod Inc Turunan-turunan kinolin-2-ona tersubstitusi alkunil yang berguna sebagai zat anti kanker
EP1107962B1 (en) 1998-08-27 2005-02-23 Pfizer Products Inc. Quinolin-2-one derivatives useful as anticancer agents
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
DE69907964T2 (de) 1998-12-23 2004-02-19 Janssen Pharmaceutica N.V. 1,2-annelierte chinolinderivate
DE60004781T2 (de) 1999-01-11 2004-07-08 Princeton University Kinase-inhibitoren mit hoher affinität zur ziel detektion und ihre verwendung
JP3989175B2 (ja) 1999-04-15 2007-10-10 ブリストル−マイヤーズ スクイブ カンパニー 環状タンパク質チロシンキナーゼ阻害剤
US7125875B2 (en) 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
EP1179541B1 (en) 1999-04-28 2004-06-16 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting VEGF
US6346625B1 (en) 1999-06-23 2002-02-12 Astrazeneca Ab Protein kinase inhibitors
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
WO2001047897A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Cytokine, especially tnf-alpha, inhibitors
FR2803592A1 (fr) 2000-01-06 2001-07-13 Aventis Cropscience Sa Nouveaux derives de l'acide 3-hydroxypicolinique, leur procede de preparation et compositions fongicides les contenant.
US6558385B1 (en) 2000-09-22 2003-05-06 Tissuelink Medical, Inc. Fluid-assisted medical device
US6692491B1 (en) 2000-03-24 2004-02-17 Scimed Life Systems, Inc. Surgical methods and apparatus for positioning a diagnostic or therapeutic element around one or more pulmonary veins or other body structures
US6776796B2 (en) 2000-05-12 2004-08-17 Cordis Corportation Antiinflammatory drug and delivery device
JP2004511541A (ja) 2000-10-17 2004-04-15 メルク　エンド　カムパニー　インコーポレーテッド チロシンキナーゼ活性を有する経口活性塩
US7105682B2 (en) 2001-01-12 2006-09-12 Amgen Inc. Substituted amine derivatives and methods of use
AR035885A1 (es) 2001-05-14 2004-07-21 Novartis Ag Derivados de 4-amino-5-fenil-7-ciclobutilpirrolo (2,3-d)pirimidina, un proceso para su preparacion, una composicion farmaceutica y el uso de dichos derivados para la preparacion de una composicion farmaceutica
WO2003024969A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
WO2003024931A1 (en) 2001-09-14 2003-03-27 Merck & Co., Inc. Tyrosine kinase inhibitors
TWI259081B (en) 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
WO2003037347A1 (en) 2001-10-30 2003-05-08 Novartis Ag Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity
WO2003057690A1 (en) 2001-12-27 2003-07-17 Theravance, Inc. Indolinone derivatives useful as protein kinase inhibitors
US7122550B2 (en) 2002-05-23 2006-10-17 Cytopia Pty Ltd Protein kinase inhibitors
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
BR0313397A (pt) 2002-08-14 2005-06-28 Vertex Pharmaceuticals Incorpo Inibidores de proteina cinase e usos destes
EP2573079A3 (en) 2002-08-23 2015-03-11 Novartis AG Benzimidazole quinolinones and uses thereof
WO2004022525A1 (en) 2002-09-05 2004-03-18 Neurosearch A/S Amide derivatives and their use as chloride channel blockers
CA2500727A1 (en) 2002-10-03 2004-04-15 Targegen, Inc. Vasculostatic agents and methods of use thereof
WO2004039782A1 (ja) 2002-10-29 2004-05-13 Kirin Beer Kabushiki Kaisha Ｆｌｔ３自己リン酸化を阻害するキノリン誘導体およびキナゾリン誘導体並びにそれらを含有する医薬組成物
KR20050075005A (ko) 2002-11-13 2005-07-19 카이론 코포레이션 암을 치료하는 방법 및 관련 방법
CL2003002353A1 (es) 2002-11-15 2005-02-04 Vertex Pharma Compuestos derivados de diaminotriazoles, inhibidores d ela proteina quinasa; composicion farmaceutica; procedimiento de preparacion; y su uso del compuesto en el tratamiento de enfermedades de desordenes alergicos, proliferacion, autoinmunes, condic
ATE425160T1 (de) 2002-12-18 2009-03-15 Vertex Pharma Benzisoxazolderivate, die sich als inhibitoren von proteinkinasen eigen
MXPA05010945A (es) 2003-04-09 2005-11-25 Japan Tobacco Inc Compuesto pentaciclico heteroaromatico y uso medicinal del mismo.
US7790724B2 (en) 2003-04-25 2010-09-07 Janssen Pharmaceutica N.V. c-fms kinase inhibitors
WO2004096795A2 (en) 2003-04-25 2004-11-11 3-Dimensional Pharmaceuticals, Inc. C-fms kinase inhibitors
US20050113566A1 (en) * 2003-04-25 2005-05-26 Player Mark R. Inhibitors of C-FMS kinase
US7427683B2 (en) * 2003-04-25 2008-09-23 Ortho-Mcneil Pharmaceutical, Inc. c-fms kinase inhibitors
CA2533812C (en) 2003-07-28 2012-12-18 Smithkline Beecham Corporation Substituted cycloalkylidene compounds
AU2004283162B2 (en) 2003-10-23 2011-12-15 Ab Science 2-aminoaryloxazole compounds as tyrosine kinase inhibitors
GB0326601D0 (en) 2003-11-14 2003-12-17 Novartis Ag Organic compounds
EP1711497A1 (en) 2004-01-30 2006-10-18 AB Science 2-(3-substituted-aryl)amino-4-aryl-thiazoles as tyrosine kinase inhibitors
US7645755B2 (en) 2004-10-22 2010-01-12 Janssen Pharmaceutical N.V. Inhibitors of c-fms kinase
KR101273434B1 (ko) * 2004-10-22 2013-06-11 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제
JP5008569B2 (ja) * 2004-10-22 2012-08-22 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ Ｃ−ｆｍｓキナーゼのインヒビターとしての芳香族アミド
NZ555289A (en) 2004-10-22 2010-10-29 Janssen Pharmaceutica Nv Inhibitors of c-fms kinase
DE102005023588A1 (de) 2005-05-18 2006-11-23 Grünenthal GmbH Salze substituierter Allophansäureester und deren Verwendung in Arzneimitteln
US20060281769A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using thienopyrimidine and thienopyridine kinase modulators
US20060281755A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
US20060281771A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminoquinoline and aminoquinazoline kinase modulators
US20060281788A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using a flt3 inhibitor and a farnesyl transferase inhibitor
US20060281700A1 (en) 2005-06-10 2006-12-14 Baumann Christian A Synergistic modulation of flt3 kinase using aminopyrimidines kinase modulators
AU2006304897B2 (en) * 2005-10-18 2012-07-12 Janssen Pharmaceutica N.V. Method of inhibiting FLT3 kinase
ES2581600T3 (es) 2006-04-20 2016-09-06 Janssen Pharmaceutica, N.V. Inhibidores de quinasa c-fms
CA2649739C (en) 2006-04-20 2015-09-01 Janssen Pharmaceutica N.V. Inhibitors of c-fms kinase
US8697716B2 (en) 2006-04-20 2014-04-15 Janssen Pharmaceutica Nv Method of inhibiting C-KIT kinase
KR101367645B1 (ko) 2006-04-20 2014-02-27 얀센 파마슈티카 엔.브이. Ｃ-ｆｍｓ 키나제의 저해제로서의 복소환식 화합물

Also Published As

Publication number Publication date
CA2702898A1 (en) 2009-04-23
TW200932738A (en) 2009-08-01
PT3208269T (pt) 2021-12-09
CY1124721T1 (el) 2022-07-22
CR11433A (es) 2011-01-14
HUE056173T2 (hu) 2022-01-28
RS62569B1 (sr) 2021-12-31
RS55860B1 (sr) 2017-08-31
ES2905118T3 (es) 2022-04-07
EP3208269B1 (en) 2021-09-15
KR20100069711A (ko) 2010-06-24
UY31397A1 (es) 2009-04-30
PL2215079T3 (pl) 2017-06-30
MX2010004263A (es) 2010-05-03
US8497376B2 (en) 2013-07-30
CN101889009B (zh) 2014-10-29
NZ584574A (en) 2011-12-22
MY153951A (en) 2015-04-15
AU2008312540B2 (en) 2014-03-27
EP2215079A1 (en) 2010-08-11
JP2011501752A (ja) 2011-01-13
BRPI0817843B8 (pt) 2021-05-25
DK3208269T3 (da) 2021-10-11
TWI440637B (zh) 2014-06-11
SI3208269T1 (sl) 2021-11-30
IL205043A (en) 2015-07-30
NI201000059A (es) 2010-09-13
HRP20170393T1 (hr) 2017-05-05
PA8799701A1 (es) 2009-05-15
CY1118717T1 (el) 2017-07-12
EA201070480A1 (ru) 2010-10-29
LT3208269T (lt) 2021-11-10
AU2008312540A1 (en) 2009-04-23
EA018936B1 (ru) 2013-11-29
EP3208269A1 (en) 2017-08-23
JP5475672B2 (ja) 2014-04-16
KR101559326B1 (ko) 2015-10-12
AR068892A1 (es) 2009-12-16
IL205043A0 (en) 2010-11-30
CA2702898C (en) 2016-10-11
LT2215079T (lt) 2017-01-25
SI2215079T1 (sl) 2017-05-31
PL3208269T3 (pl) 2022-01-10
BRPI0817843A2 (pt) 2015-04-07
CL2008003068A1 (es) 2009-03-06
CN101889009A (zh) 2010-11-17
PT2215079T (pt) 2017-03-23
ZA201003429B (en) 2011-08-31
EP2215079B1 (en) 2016-12-14
BRPI0817843B1 (pt) 2019-01-02
CO6270363A2 (es) 2011-04-20
HRP20211593T1 (hr) 2022-03-18
DK2215079T3 (en) 2017-02-13
ES2614754T3 (es) 2017-06-01
US20090105296A1 (en) 2009-04-23
WO2009052237A1 (en) 2009-04-23
PE20090972A1 (es) 2009-07-13
UA99311C2 (en) 2012-08-10
JO3240B1 (ar) 2018-03-08

Similar Documents

Publication Publication Date Title
DK2215079T3 (en) INHIBITORS OF C-FMS KINASE
TWI411612B (zh) Ｃ-ｆｍｓ激酶之抑制劑
BRPI0707872A2 (pt) arildiidroisoquinolinonas substituÍdas por azaciclila, processo para sua preparaÇço e seu uso como medicamentos
KR20230002419A (ko) Bcl-2 억제제
KR20200136384A (ko) 통증 치료용 화합물
KR20230035621A (ko) Mcl-1의 억제제로서 인돌 유도체를 함유하는 마크로사이클릭 에테르
CN116589466A (zh) 通过缀合btk抑制剂与e3连接酶配体降解布鲁顿氏酪氨酸激酶(btk)及其使用方法
CN112469722A (zh) 作为a2a受体拮抗剂的吡唑并三唑并嘧啶衍生物
AU2013203813B2 (en) Inhibitors of C-FMS kinase
KR20230124608A (ko) 무스카린성 아세틸콜린 수용체 m4의 길항제